Baidu
map

Radiother Oncol: 山东大学研究者发现缺氧诱导CDUPRT/5-FC基因治疗方案能特异性靶向缺氧肿瘤细胞

2013-05-16 Radiother Oncol dxy

对于绝大多数的实体肿瘤而言,缺氧是其显著特征。有证据提示,在局部晚期实体肿瘤中,50%-60%的实体肿瘤表现出缺氧区域分布的不均匀。既往进行的临床研究提示与氧供好的肿瘤相比,治疗对乏氧肿瘤的局部控制较差,并且患者的总体生存情况显著降低。鉴于缺氧在肿瘤进展和对治疗的耐药中所起到的主要作用,研究者考虑到能将缺氧作为一个治疗靶点对肿瘤的治疗方案进行新的探究。为了探究当与5-氟胞嘧啶方案联用时,缺氧是否能

对于绝大多数的实体肿瘤而言,缺氧是其显著特征。有证据提示,在局部晚期实体肿瘤中,50%-60%的实体肿瘤表现出缺氧区域分布的不均匀。既往进行的临床研究提示与氧供好的肿瘤相比,治疗对乏氧肿瘤的局部控制较差,并且患者的总体生存情况显著降低。鉴于缺氧在肿瘤进展和对治疗的耐药中所起到的主要作用,研究者考虑到能将缺氧作为一个治疗靶点对肿瘤的治疗方案进行新的探究。为了探究当与5-氟胞嘧啶方案联用时,缺氧是否能通过靶向作用于双功能自杀基因的胞嘧啶脱氨酶和尿嘧啶磷酸核糖基转移酶表达而增强肿瘤对放疗的反应,来自中国山东大学的Xiaorong Sun等设计了相关研究并将其研究结果发表在Radiother Oncol 2012年10月的期刊上。
在诱导缺氧的启动子的控制下,研究者制备了稳定转染的R3327-AT细胞,该细胞表达三重融合基因——CD、UPRT和mDsRed。研究者通过蛋白质印迹法、流式细胞技术、荧光显微镜技术和对5-FU和5-FC的细胞毒性测定来验证缺氧所诱导的CDUPRTmDsRed的表达/功能。随之,研究者采用5-FC和局部放疗对荷瘤小鼠进行治疗。同时,研究者对肿瘤的体积进行了监测,并且比较了同时接受5-FC和放疗的小鼠和仅接受5-FC或放疗的小鼠在治疗前后肿瘤体积的变化情况。此外,研究者还采用荧光显微镜记录了在肿瘤组织中CDUPRTmDsRed在缺氧区的分布情况。
研究结果显示缺氧所诱导的CDUPRTmDsRed蛋白可增高肿瘤对5-FC和5-FU的敏感性。在缺氧情况下,经过5-FC治疗后放疗增敏效应显著增高。在肿瘤的异种移植物中,荧光显微镜下的CDUPRTmDsRed表达与缺氧标记物(哌莫硝唑染色阳性的细胞)相互局限。此外,与仅接受5-FC或放疗治疗的荷瘤小鼠相比,接受联合5-FC和放疗的荷瘤小鼠的肿瘤体积缩小更加明显。
来自本研究的数据提示,缺氧诱导的CDUPRT/5-FC基因治疗方案能特异性的针对缺氧肿瘤细胞,并且与放疗联合时能显著改善对肿瘤的控制。
缺氧相关的拓展阅读:


Hypoxia targeted bifunctional suicide gene expression enhances radiotherapy in vitro and in vivo.
PURPOSE
To investigate whether hypoxia targeted bifunctional suicide gene expression-cytosine deaminase (CD) and uracil phosphoribosyltransferase (UPRT) with 5-FC treatments can enhance radiotherapy.
MATERIALS AND METHODS
Stable transfectants of R3327-AT cells were established which express a triple-fusion-gene: CD, UPRT and monomoric DsRed (mDsRed) controlled by a hypoxia inducible promoter. Hypoxia-induced expression/function of CDUPRTmDsRed was verified by western blot, flow cytometry, fluorescent microscopy, and cytotoxicity assay of 5-FU and 5-FC. Tumor-bearing mice were treated with 5-FC and local radiation. Tumor volume was monitored and compared with those treated with 5-FC or radiation alone. In addition, the CDUPRTmDsRed distribution in hypoxic regions of tumor sections was visualized with fluorescent microscopy.
RESULTS
Hypoxic induction of CDUPRTmDsRed protein correlated with increased sensitivity to 5-FC and 5-FU. Significant radiosensitization effects were detected after 5-FC treatments under hypoxic conditions. In the tumor xenografts, the distribution of CDUPRTmDsRed expression visualized with fluorescence microscopy was co-localized with the hypoxia marker pimonidazole positive staining cells. Furthermore, administration of 5-FC to mice in combination with local irradiation resulted in significant tumor regression, as in comparison with 5-FC or radiation treatments alone.
CONCLUSIONS
Our data suggest that the hypoxia-inducible CDUPRT/5-FC gene therapy strategy has the ability to specifically target hypoxic cancer cells and significantly improve the tumor control in combination with radiotherapy.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]
    2015-02-28 xiaoai5777

    不错的文章,学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]
    2014-04-24 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=17226, encodeId=69611e22685, content=不错的文章,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Sat Feb 28 11:06:00 CST 2015, time=2015-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032713, encodeId=3cfa2032e1340, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Apr 24 17:08:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899040, encodeId=d7fe18990401a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Feb 19 19:08:00 CST 2014, time=2014-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864451, encodeId=7a891864451b1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Fri Sep 20 22:08:00 CST 2013, time=2013-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792953, encodeId=a8691e9295323, content=<a href='/topic/show?id=34211508e37' target=_blank style='color:#2F92EE;'>#Radiother#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15087, encryptionId=34211508e37, topicName=Radiother)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Thu Mar 13 07:08:00 CST 2014, time=2014-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904929, encodeId=2e2d19049299e, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Tue Sep 17 02:08:00 CST 2013, time=2013-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312879, encodeId=797613128e92a, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Sat May 18 04:08:00 CST 2013, time=2013-05-18, status=1, ipAttribution=)]

相关资讯

JCMM:HIF-1α激活瞬时受体TRPC通道促进轻度缺氧心肌细胞肥大

近日,国际著名杂志《细胞与分子医学期刊》(Journal of Cellular and Molecular Medicine)发表了哈尔滨医科大学的一项研究成果,首次证实了轻度缺氧HIF-1α可以调控心肌肥厚,可望为生理性或病理性心肌肥厚的防治提供新的靶点和药物干预策略。 这篇题为《缺氧诱导因子HIF-1α激活瞬时受体TRPC通道促进轻度缺氧心肌细胞肥大》的论文是哈医大药学院青年专家初文峰教授

Neural Regen Res :三七总皂苷减轻缺氧复氧所致神经元的氧化应激损伤

《中国神经再生研究(英文版)》杂志于2012年12月36期出版的一项关于“Panax notoginseng saponin attenuates hypoxia/ reoxygenation-induced oxidative stress in cortical neurons”的研究发现:三七总皂甙可①显着增强缺氧复氧损伤神经元的活力。②降低缺氧复氧损伤神经元丙二醛和一氧化氮的含量。③提高缺

Mol Cancer Res:SDF-1/CXCR4信号轴与乳腺癌转移密切相关

SDF-1/CXCR4信号轴已被证实与乳腺癌转移有着密切联系。相比较于其在某些器官特异性肿瘤细胞归巢转移和定居中的作用,其在血管内特别是在缺氧的环境下是如何发挥作用的仍然知之甚少。 最初,研究发现趋化因子SDF-1及其受体CXCR4存在于浸润性导管癌标本组织的微血管中。近来,为了阐明肿瘤血管内皮细胞中SDF-1/CXCR4信号轴在肿瘤细胞入血管中的作用,研究人员选用人脐静脉内皮细胞和真皮微血管内

PLoS ONE:缺氧调节的溶瘤腺病毒基因治疗

6月15日,PLoS ONE在线报道了缺氧调节溶瘤腺病毒治疗肿瘤的研究进展。缺氧是一个微环境因素,有助于肿瘤细胞的侵袭,进展和转移。缺氧肿瘤细胞往往会比常氧肿瘤细胞表现出更大的放化疗抵抗能力。这表明人类需要新型抗癌疗法有效地消除缺氧肿瘤细胞。 以往研究发明了肿瘤特异的复制性溶瘤腺病毒(OBP-301:Telomelysin)。其中,人端粒酶逆转录酶(hTERT)启动子驱动病毒E1的表达。 hTE

Baidu
map
Baidu
map
Baidu
map